References Nordli DR Jr., Kuroda MM, Carroll J, Koenigsberger DY, Hirsch LJ, Bruner HJ, et al
Diabetes care , 26 (6), 1902-1912
Key Takeaways Agonism Profile: Tirzepatide is a dual GLP-1/GIP agonist, while Retatrutide is a "triple agonist" targeting GLP-1, GIP, and Glucagon receptors
The peptide appears to shift cellular body function toward anabolic processes, favoring protein synthesis and muscle growth while possibly reducing fat buildup
While prescription GLP-1 medications have dominated headlines, a growing number of people are exploring whether certain probiotic strains might offer a different path forward-one that works with the body's natural systems rather than introducing synthetic compounds
But, some of these side effects may be controlled by changes in diet and hydration as you adjust to the medication